Search results for "HIV infections"

showing 10 items of 304 documents

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/…

2017

Background: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens. Objectives: We aimed to explore the efficacy and tolerability of switching to darunavir/ritonavir (DRV/r) plus raltegravir (RAL) while having a viral load (VL) ≤50 copies/mL in the clinical setting. Study design: Treatment-experienced HIV 1-infected patients enrolled in the ICONA Foundation Study cohort were included if they switched their current regimen to DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Different defin…

0301 basic medicineMaleHIV InfectionsAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability; Microbiology (medical); Infectious DiseasesAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability; Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; RNA Viral; Raltegravir Potassium; Ritonavir; Viral LoadGastroenterologyCohort StudiesAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability0302 clinical medicineMedicineNRTI-sparing regimen030212 general & internal medicineViralDarunavireducation.field_of_studyLamivudineGeneral MedicineMiddle AgedViral LoadTolerabilityAntiretroviral therapyInfectious DiseasesTolerabilityItalyCombinationRNA ViralDrug Therapy CombinationFemaleViral loadmedicine.drugAdultMicrobiology (medical)medicine.medical_specialtyEfficacyAnti-HIV Agents030106 microbiologyPopulationDarunavir/ritonavir; Raltegravir; Efficacy; Tolerability; Antiretroviral therapy; NRTI-sparing regimenSettore MED/17 - MALATTIE INFETTIVELower riskNO03 medical and health sciencesDrug TherapyInternal medicineRaltegravir PotassiumHumanseducationDarunavirRitonavirbusiness.industryDarunavir/ritonavirRaltegravirRaltegravirHIV-1RNARitonavirbusinessAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability;
researchProduct

Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized…

2016

International audience; IMPORTANCE:Data on long-term immune responses to hepatitis B virus (HBV) vaccination in adults with human immunodeficiency virus 1 (HIV-1) infection are scarce.OBJECTIVE:To compare long-term (up to month 42) immune responses to the standard HBV vaccination regimen with a 4-injection intramuscular double-dose regimen and a 4-injection intradermal low-dose regimen.DESIGN, SETTING, AND PARTICIPANTS:The phase 3, open-label, multicenter parallel-group (1:1:1 allocation ratio) randomized clinical trial was conducted from June 28, 2007, to October 23, 2008, at 33 centers in France. Participants included 437 HBV-seronegative adults with HIV-1 and CD4 cell counts of more than…

0301 basic medicineMaleHIV Infectionsmedicine.disease_causelaw.inventionMESH: HIV-10302 clinical medicineRandomized controlled triallawSingle-Blind Method030212 general & internal medicineMESH: Hepatitis B AntibodiesMESH: Treatment Outcomeeducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: Middle AgedVaccinationMESH: Follow-Up StudiesMESH: HIV InfectionsHepatitis BMiddle Aged16. Peace & justiceHepatitis BMESH: Injections Intramuscular3. Good healthVaccinationTreatment OutcomeFemaleFranceIntramuscular injectionAdultmedicine.medical_specialtyHepatitis B vaccineInjections Intradermal030106 microbiologyPopulationInjections Intramuscular03 medical and health sciencesInternal medicineInternal MedicinemedicineHumansHepatitis B VaccinesHepatitis B AntibodieseducationHepatitis B virusMESH: Injections IntradermalMESH: Hepatitis B VaccinesMESH: HumansMESH: Hepatitis Bbusiness.industryMESH: AdultMESH: Vaccinationmedicine.diseaseMESH: Single-Blind MethodMESH: MaleSurgeryMESH: FranceRegimenHIV-1MESH: BiomarkersbusinessMESH: FemaleBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Vitamin D Status and the Relationship with Bone Fragility Fractures in HIV-Infected Patients: A Case Control Study

2018

HIV-infected patients show high risk of fracture. The aims of our study were to determine the prevalence of vertebral fractures (VFs) and their associations with vitamin D in HIV patients. 100 patients with HIV infection and 100 healthy age-and sex-matched controls were studied. Bone mineral density was measured by quantitative ultrasound at the non-dominant heel. Serum osteocalcin and C-terminal telopeptide of collagen type 1 served as bone turnover markers. Bone ultrasound measurements were significantly lower in patients compared with controls (Stiffness Index (SI): 80.58 ± 19.95% vs. 93.80 ± 7.10%, respectively, p < 0.001). VFs were found in 16 patients and in 2 controls. HIV patie…

0301 basic medicineMaleHeelBone ultrasound; HIV; Osteoporosis; Vertebral fractures; Vitamin D; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryOsteoporosisvitamin DHIV InfectionsGastroenterologyCatalysiBone remodelingFractures Bone0302 clinical medicineRisk Factors030212 general & internal medicineSpectroscopyBone mineralUltrasoundComputer Science Applications1707 Computer Vision and Pattern RecognitionPhosphorusGeneral MedicineMiddle AgedComputer Science Applicationsmedicine.anatomical_structureFemaleAdultmedicine.medical_specialtybone ultrasoundCatalysisArticleInorganic Chemistrybone ultrasound; HIV; osteoporosis; vertebral fractures; vitamin D03 medical and health sciencesN-terminal telopeptideInternal medicinemedicineVitamin D and neurologyHumansvertebral fracturesPhysical and Theoretical ChemistryMolecular Biologybusiness.industryOrganic ChemistryOsteoporosiCase-control studyHIVmedicine.diseaseosteoporosis030104 developmental biologyCase-Control StudiesCalciumVertebral fracturebusinessInternational Journal of Molecular Sciences
researchProduct

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

2019

AbstractObjectivesTo evaluate the incidence and risk factors for liver enzyme elevations (LEE) in patients initiating first-line ART in the ICONA prospective observational cohort, between June 2009 and December 2017.Patients and methodsIn total, 6575 ART-naive patients were selected, initiating two NRTIs with the third drug being a boosted PI (n=2436; 37.0%), an NNRTI (n=2384; 36.3%) or an integrase strand transfer inhibitor (INSTI) (n=1755; 26.7%). HBV surface antigen and HCV RNA were detected in 3.9% and 5.8% of the study population. Inverse probability weighted Cox regression analysis was used to calculate the HRs, according to first-line regimen, for LEE, defined as ALT or AST increases…

0301 basic medicineMaleIntegrase inhibitorHepatitis B Surface AntigenHIV Infections0302 clinical medicineRisk Factorshivh epatitis c rna surface antigens follow-up homosexuality integrase inhibitors hepatitis b virus hepatitis b virus measurement hiv infections hepatotoxicity hepatitis c virus coinfection nucleoside reverse transcriptase inhibitors non-nucleoside reverse transcriptase inhibitors cox proportional hazards models baseline value liver enzyme raltegravirPharmacology (medical)HIV Infection030212 general & internal medicineProspective StudiesProspective cohort studyCoinfectionIncidence (epidemiology)Liver DiseaseIncidenceLiver Diseasesvirus diseasesHepatitis CMiddle AgedHepatitis CReverse Transcriptase InhibitorInfectious DiseasesCohortCoinfectionPopulation studyRegression AnalysisReverse Transcriptase InhibitorsFemalemedicine.drugHumanMicrobiology (medical)Adultmedicine.medical_specialtyAnti-HIV AgentsRegression AnalysiNO03 medical and health sciencesInternal medicinemedicineHumansHIV Integrase InhibitorsHIV Protease InhibitorPharmacologyHepatitis B Surface Antigensbusiness.industryAnti-HIV AgentHIV ARTHIV Protease Inhibitorsmedicine.diseaseRaltegravir030112 virologyHIV Integrase InhibitorProspective StudieHIV-1businessAdult Anti-HIV Agents Coinfection Female Hepatitis B Surface Antigens Hepatitis C HIV Infections HIV Integrase Inhibitors HIV Protease Inhibitors HIV-1 Humans Incidence Liver Diseases Male Middle Aged Prospective Studies Regression Analysis Reverse Transcriptase Inhibitors Risk Factors
researchProduct

DRH1 - a novel blood-based HPV tumour marker.

2020

Abstract Background To date, no studies have successfully shown that a highly specific, blood-based tumour marker to detect clinically relevant HPV-induced disease could be used for screening, monitoring therapy response or early detection of recurrence. This study aims to assess the clinical performance of a newly developed HPV16-L1 DRH1 epitope-specific serological assay. Methods In a multi-centre study sera of 1486 patients (301 Head and Neck Squamous Cell Carcinoma (HNSCC) patients, 12 HIV+ anal cancer patients, 80 HIV-positive patients, 29 Gardasil-9-vaccinees, 1064 healthy controls) were tested for human HPV16-L1 DRH1 antibodies. Analytical specificity was determined using WHO referen…

0301 basic medicineMaleResearch paperlcsh:MedicineHIV InfectionsDiseaseGastroenterologyHNSCC0302 clinical medicineNeoplasmsTumour markerMedicineProspective StudiesAged 80 and overlcsh:R5-920Human papillomavirus 16medicine.diagnostic_testbiologyGeneral MedicineMiddle AgedAnus NeoplasmsVaccinationHead and Neck Neoplasms030220 oncology & carcinogenesisArea Under CurveCarcinoma Squamous CellScreeningBiomarker (medicine)FemaleAntibodylcsh:Medicine (General)Blood testAdultHPV16medicine.medical_specialtyEarly detectionSensitivity and SpecificityGeneral Biochemistry Genetics and Molecular BiologyAntibodies03 medical and health sciencesInternal medicineBiomarkers TumorBlood testAnal cancerHumansPapillomavirus VaccinesAgedbusiness.industrylcsh:RPapillomavirus InfectionsOncogene Proteins Viralmedicine.diseaseHead and neck squamous-cell carcinoma030104 developmental biologyCross-Sectional StudiesCase-Control Studiesbiology.proteinCapsid ProteinsbusinessCarrier ProteinsEBioMedicine
researchProduct

Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

2018

Objectives: The aim was to evaluate the evolution of transmitted HIV-1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)-naïve patients from 2006 to 2016. Methods: HIV-1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. Results: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169–521 cells/μL], and the median viral load was 4.7 log 10 HIV-1 RNA copies/mL (IQR …

0301 basic medicineMaleantiretroviral therapy; HIV; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Mutation; Odds Ratio; Prevalence; Viral Proteins; Drug Resistance Viralantiretroviral therapy; HIV; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance; Health Policy; Infectious Diseases; Pharmacology (medical)Drug ResistanceHIV InfectionsDrug resistanceGastroenterologyInterquartile rangeOdds RatioPrevalenceHIV InfectionPharmacology (medical)ViralbiologyHealth PolicyMiddle AgedIntegraseInfectious DiseasesItalyFemaleViral loadHumanresistance epidemiologyAdultmedicine.medical_specialtytransmitted HIV drug resistanceAnti-HIV AgentsHIV; antiretroviral therapy; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance030106 microbiologyantiretroviral therapySettore MED/17 - MALATTIE INFETTIVEVirus03 medical and health sciencesrecent HIV infectionViral ProteinsInternal medicineDrug Resistance ViralmedicineViral ProteinHumansbusiness.industryAnti-HIV AgentHIVOdds ratioReverse transcriptaseConfidence intervalCD4 Lymphocyte CountMutationbiology.proteinHIV-1business
researchProduct

CD3ε Expression Defines Functionally Distinct Subsets of Vδ1 T Cells in Patients With Human Immunodeficiency Virus Infection

2018

Human γδ T cells expressing the Vδ1 T cell receptor (TCR) recognize self and microbial antigens and stress-inducible molecules in a major histocompatibility complex -unrestricted manner and are an important source of innate interleukin-17. Vδ1 T cells are expanded in the circulation and intestines of patients with human immunodeficiency virus (HIV) infection. In the present study, we show that patients with HIV have elevated frequencies, but not absolute numbers, of circulating Vδ1 T cells compared to control subjects. This increase was most striking in the patients with Candida albicans co-infection. Using flow cytometry and confocal microscopy, we identify two populations of Vδ1 T cells, …

0301 basic medicineMalelcsh:Immunologic diseases. AllergyCD3 ComplexCD3T cellVδ1 T cellsImmunologyGene ExpressionHIV InfectionsMajor histocompatibility complexFlow cytometryImmunophenotypinginterleukin-1703 medical and health sciencesImmunophenotypingAntigenT-Lymphocyte SubsetsmedicineHumansImmunology and AllergyLymphocyte CountOriginal Researchprogrammed death-1biologymedicine.diagnostic_testhuman immunodeficiency virusCoinfectionflow cytometryT-cell receptorCandidiasisReceptors Antigen T-Cell gamma-deltaMolecular biology030104 developmental biologymedicine.anatomical_structurebiology.proteinHIV-1CytokinesFemaleInterleukin 17lcsh:RC581-607CD3εBiomarkersFrontiers in Immunology
researchProduct

Evaluation of HIV transmission clusters among natives and foreigners living in Italy

2020

We aimed at evaluating the characteristics of HIV-1 molecular transmission clusters (MTCs) among natives and migrants living in Italy, diagnosed between 1998 and 2018. Phylogenetic analyses were performed on HIV-1 polymerase (pol) sequences to characterise subtypes and identify MTCs, divided into small (SMTCs, 2&ndash

0301 basic medicineMalelcsh:QR1-502SubtypeHIV InfectionsmigrantsBioinformatics; Cluster detection; Drug resistance testing; Human immunodeficiency virus (HIV); Migrants; Molecular epidemiology; Phylogenetic analysis; Risk factors; Subtypes; Transmission networks and clusters; Adult; Cohort Studies; Female; Genotype; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Sexual and Gender Minorities; pol Gene Products Human Immunodeficiency Virus; Emigrants and Immigrants; Phylogenylcsh:MicrobiologyMen who have sex with menCohort StudiesSexual and Gender Minorities0302 clinical medicineGenotypehuman immunodeficiency virus (HIV); molecular epidemiology; phylogenetic analysis; migrants; cluster detection; transmission networks and clusters; subtypes; drug resistance testing; risk factors; bioinformaticsMedicinerisk factors030212 general & internal medicinepol Gene ProductsHiv transmissionPhylogenySubtypesPhylogenetic analysisTransmission (medicine)subtypesvirus diseasesHuman immunodeficiency virus (HIV)bioinformaticsMiddle AgedTransmission networks and clustersCluster detectionInfectious DiseasesItalyMolecular epidemiologyCohortFemaleHuman Immunodeficiency VirusCohort studyAdultmedicine.medical_specialtyGenotypeBioinformaticsEmigrants and ImmigrantsMigrantsArticleNO03 medical and health sciencesPhylogenetic analysiVirologyHumansBioinformaticMolecular epidemiologybusiness.industryPublic healthphylogenetic analysisMigrantDrug resistance testingSettore MED/17030104 developmental biologyRisk factorspol Gene Products Human Immunodeficiency Virustransmission networks and clustersTransmission networks and clusters.HIV-1Risk factorbusinessDemography
researchProduct

Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study

2020

This article belongs to the Special Issue Role of Prebiotics and Probiotics in Health and Disease.

0301 basic medicineMalemedicine.medical_specialtyChildren and adolescentsTime FactorsHuman immunodeficiency virus (HIV)HIV Infectionslcsh:TX341-641Diseasemedicine.disease_causedigestive systemArticle03 medical and health sciences0302 clinical medicineDouble-Blind MethodIntervention (counseling)Internal medicineHiv infectedmedicinemicrobiotaHumans030212 general & internal medicineChildSymbiosisNutrition and Dieteticsbusiness.industryMicrobiotaProbioticsHIVInfectious Disease Transmission VerticalGastrointestinal MicrobiomePilots030104 developmental biologyPrebioticsAnti-Retroviral Agentschildren and adolescentsChild PreschoolDietary SupplementsVertical transmissionDysbiosisFemalevertical transmissionbusinessChild Nutritional Physiological Phenomenalcsh:Nutrition. Foods and food supplyFood ScienceNutrients
researchProduct

Elevated Fatty Liver Index as a Risk Factor for All‐Cause Mortality in Human Immunodeficiency Virus–Hepatitis C Virus–Coinfected Patients (ANRS CO13 …

2020

International audience; Background and aims: Human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients are at high risk of metabolic complications and liver-related events, which are both associated with hepatic steatosis and its progressive form, nonalcoholic steatohepatitis, a known risk factor for mortality. The fatty liver index (FLI), a noninvasive steatosis biomarker, has recently drawn attention for its clinical prognostic value, although its capacity to predict mortality risk in HIV-HCV-coinfected patients has never been investigated. Using a Cox proportional hazards model for mortality from all causes, with data from the French National Agency for Research on A…

0301 basic medicineMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatment[SDV]Life Sciences [q-bio]HIV InfectionsLiver transplantationmedicine.disease_causeGastroenterologyAntiviral AgentsCohort Studies03 medical and health sciences0302 clinical medicineRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicineCause of DeathmedicineHumansRisk factorComputingMilieux_MISCELLANEOUSHepatologybusiness.industryCoinfectionHazard ratioFatty liverHepatitis C ChronicMiddle Agedmedicine.disease3. Good healthFatty Liver[SDV] Life Sciences [q-bio]030104 developmental biology[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases030211 gastroenterology & hepatologyFemaleFranceSteatosisViral hepatitisbusiness
researchProduct